Rudolf  Likar,Gerhard  Nahler,
Surprising Long Term Survival in Glioblastoma Patients Treated with Cannabidiol
Clinical Oncology and Research
2023
2613-4942
http://dx.doi.org/10.31487/j.COR.2023.01.05
https://www.sciencerepository.org/surprising-long-term-survival_COR-2023-1-105 
Abstract: Glioblastoma multiforme (GBM) is one of the most deadly tumors; even with aggressive radiochemotherapy, mean survival rates are only around 14 to 16 months post diagnose. Here we present the follow-up of 15 patients with GBM that have received concomitant cannabidiol (CBD) in addition to standard therapy, and that have been reported in details two years ago. 
The survival time of patients is presented together with prognostic factors such as age at diagnose, molecular markers and dose of CBD. 
The actual median survival time is 28 months, the arithmetic mean is 30.9 months, therefore about three to five times longer than expected. When comparing the group of patients surviving less than 28 months with those who lived longer, we found that all subjects who received a low dose of CBD (200mg per day) were in the group surviving less than 28 months. Apart from the daily dose of CBD, no striking difference was observed for other prognostic factors. 
It is concluded that CBD contributed to the long term survival of GBM patients, and that this effect depends on the dose.Keywords: Cannabidiol, CBD, glioblastoma multiforme, long term survival, prognostic factors